Literature DB >> 25759620

Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers.

Kerstin Rhiem1, Rita Schmutzler1.   

Abstract

Unlike the general decrease in invasive oncologic care, the trend for prophylactic bilateral mastectomy in healthy women and prophylactic contralateral mastectomy in women with unilateral breast cancer is steadily rising. This is even more surprising when considering that for e.g. prophylactic contralateral mastectomy no clear survival benefit has been demonstrated so far. The decision-making process around risk-reducing surgery may be influenced by several conflicting parameters such as the patient's fears and desire to achieve a survival advantage, the surgeon's financial motivations, or the oncologist's paternalistic approach to the above trend. Physicians should support their patients throughout the decision-making process, guide them through the dense fog of information, and encourage them to reconsider all options and alternatives before embarking on an irreversible surgical intervention. Healthy and diseased women should be comprehensively informed about their absolute individual risks for cancer, the benefits and harms of the surgery, alternative preventive strategies, and last but not least the competing risks of preceding carcinomas and cancer in general. Within the framework of non-directive counseling in the specialized centers of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC), decision-making aids are being developed with grants from the Federal Ministry of Health and the German Cancer Aid to support women in making conclusive and satisfactory decisions.

Entities:  

Keywords:  BRCA1; BRCA2; High-risk genes; Prophylactic mastectomy

Year:  2014        PMID: 25759620      PMCID: PMC4317675          DOI: 10.1159/000369592

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  26 in total

1.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

3.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

Authors:  Nasim Mavaddat; Susan Peock; Debra Frost; Steve Ellis; Radka Platte; Elena Fineberg; D Gareth Evans; Louise Izatt; Rosalind A Eeles; Julian Adlard; Rosemarie Davidson; Diana Eccles; Trevor Cole; Jackie Cook; Carole Brewer; Marc Tischkowitz; Fiona Douglas; Shirley Hodgson; Lisa Walker; Mary E Porteous; Patrick J Morrison; Lucy E Side; M John Kennedy; Catherine Houghton; Alan Donaldson; Mark T Rogers; Huw Dorkins; Zosia Miedzybrodzka; Helen Gregory; Jacqueline Eason; Julian Barwell; Emma McCann; Alex Murray; Antonis C Antoniou; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2013-04-29       Impact factor: 13.506

4.  Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.

Authors:  Kristin Bosse; Kerstin Rhiem; Barbara Wappenschmidt; Martin Hellmich; Martin Madeja; Monika Ortmann; Peter Mallmann; Rita Schmutzler
Journal:  Gynecol Oncol       Date:  2006-08-09       Impact factor: 5.482

5.  Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.

Authors:  Tari A King; Rita Sakr; Sujata Patil; Inga Gurevich; Michelle Stempel; Michelle Sampson; Monica Morrow
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

6.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

7.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

8.  Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment.

Authors:  Todd M Tuttle; Elizabeth B Habermann; Erin H Grund; Todd J Morris; Beth A Virnig
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

9.  The Angelina effect: immediate reach, grasp, and impact of going public.

Authors:  Dina L G Borzekowski; Yue Guan; Katherine C Smith; Lori H Erby; Debra L Roter
Journal:  Genet Med       Date:  2013-12-19       Impact factor: 8.822

10.  The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.

Authors:  Kerstin Rhiem; Christoph Engel; Monika Graeser; Silke Zachariae; Karin Kast; Marion Kiechle; Nina Ditsch; Wolfgang Janni; Christoph Mundhenke; Michael Golatta; Dominic Varga; Sabine Preisler-Adams; Tilman Heinrich; Ulrich Bick; Dorothea Gadzicki; Susanne Briest; Alfons Meindl; Rita K Schmutzler
Journal:  Breast Cancer Res       Date:  2012-12-07       Impact factor: 6.466

View more
  7 in total

1.  Surgical Treatment of Breast Cancer in BRCA-Mutation Carriers.

Authors:  Vahit Özmen
Journal:  J Breast Health       Date:  2015-07-01

2.  Prepectoral breast reconstruction with complete anterior implant coverage using a single, large, square-shaped acellular dermal matrix.

Authors:  Hyun Ki Hong; Yun Hyun Kim; Joon Seok Lee; Jeeyeon Lee; Ho Yong Park; Jung Dug Yang
Journal:  BMC Surg       Date:  2022-06-20       Impact factor: 2.030

3.  Hereditary breast cancer: screening and risk reducing surgery.

Authors:  Matteo Renzulli; Simone Zanotti; Alfredo Clemente; Giangaspare Mineo; Francesco Tovoli; Alfonso Reginelli; Antonio Barile; Salvatore Cappabianca; Mario Taffurelli; Rita Golfieri
Journal:  Gland Surg       Date:  2019-09

4.  Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.

Authors:  Hemant Malhotra; Pradnya Kowtal; Nikita Mehra; Raja Pramank; Rajiv Sarin; Thangarajan Rajkumar; Sudeep Gupta; Ajay Bapna; Gouri Shankar Bhattacharyya; Sabhyata Gupta; Amita Maheshwari; Ashraf U Mannan; Ravindra Reddy Kundur; Rupinder Sekhon; Manish Singhal; B K Smruti; Somashekhar Sp; Moushumi Suryavanshi; Amit Verma
Journal:  JCO Glob Oncol       Date:  2020-07

5.  Nurse-led decision coaching by specialized nurses for healthy BRCA1/2 gene mutation carriers - adaptation and pilot testing of a curriculum for nurses: a qualitative study.

Authors:  Birte Berger-Höger; Frank Vitinius; Hannah Fischer; Karolina Beifus; Juliane Köberlein-Neu; Anna Isselhard; Maren Töpper; Regina Wiedemann; Kerstin Rhiem; Rita Schmutzler; Stephanie Stock; Anke Steckelberg
Journal:  BMC Nurs       Date:  2022-02-10

6.  Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome.

Authors:  Javier A Menendez; Núria Folguera-Blasco; Elisabet Cuyàs; Salvador Fernández-Arroyo; Jorge Joven; Tomás Alarcón
Journal:  Oncotarget       Date:  2016-03-15

7.  Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.

Authors:  Michael G Schrauder; Lisa Brunel-Geuder; Lothar Häberle; Marius Wunderle; Juliane Hoyer; Roland Csorba; André Reis; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Michael P Lux
Journal:  Eur J Med Res       Date:  2019-09-14       Impact factor: 2.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.